Novartis CEO Vasant Narasimhan on Transforming a 250-Year-Old Company
Summary
In this episode Vasant Narasimhan discusses Novartis’s strategic transformation from a diversified conglomerate into a focused, pure‑play medicines company that unlocked roughly $180 billion in shareholder value. He outlines the company’s R&D concentration on three platform technologies—cell & gene therapies, RNA (including siRNA) medicines, and radioligand therapies—applied across oncology, immunology, neuroscience, and cardiorenal. Narasimhan assesses the current state of those modalities (cell therapies maturing with manufacturing gains; RNA medicines de‑risking toward infrequent dosing) and positions AI as an enabling but not instantaneous solution for discovery. He also gives practical advice to entrepreneurs and investors: be crystal clear about where a drug fits in the treatment paradigm, perform the decisive “killer experiments,” and don’t underinvest in CMC/manufacturing work. The conversation touches on competitive shifts (notably China’s biotech rise), regulatory timing, and the long timelines required for drug approvals even with AI assistance.
Key Takeaways
- 1Novartis is strategically focusing R&D on three platform technologies to drive high‑value medicines.
- 2Cell therapies are progressing but have under‑realized potential; manufacturing improvements are critical.
- 3RNA medicines (siRNA) are maturing into a de‑risked, high‑impact modality with potential for infrequent dosing.
- 4AI is an enabling force across R&D but will not produce fully AI‑discovered, approved drugs overnight.
- 5Entrepreneurs must prove clinical fit early with 'killer experiments' and properly fund CMC/manufacturing work.
Notable Quotes
"We unlocked almost $180 billion of value."
"It costs over $2 million, and it's reimbursed in 48 countries."
"I would say right now, [cell and gene therapies are] punching below their potential."
"In R&D, it'll take seven to 10 years because that's just how long it takes to develop drugs."
""that if you treat earlier, you're going to win.""
""We're looking for those killer experiments.""
""The CMC work we consistently see is underinvested in.""
Episode questions
What platform technologies is Novartis prioritizing?
Novartis focuses on cell & gene therapies, RNA medicines (including siRNA), and radioligand therapies, alongside core small molecules and biologics to apply across oncology, immunology, neuroscience and cardiorenal areas.
Why did Novartis spin off multiple businesses to become a pure‑play medicines company?
Leadership concluded capital was being misallocated across diverse businesses, requiring the pharmaceutical core to be sub‑optimized; focusing on biopharmaceuticals aligned culture, expertise and returns for investors.
Are cell therapies currently living up to expectations?
Narasimhan says they're punching below their potential to date, but new indications (immune reset for autoimmune disease), encouraging sentinel patient results, and manufacturing advances (shorter vein‑to‑vein times) point to rapid maturation.
How should we think about AI's timing and impact in drug discovery?
AI is an enabling technology across the R&D chain; it can shorten timelines and improve success probabilities, but fully AI‑derived drug candidates will still take many years (7–10+) to progress through development and approval.